BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37685923)

  • 1. Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer.
    Levink IJM; Jansen MPHM; Azmani Z; van IJcken W; van Marion R; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
    Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
    J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An 8q24 Gain in Pancreatic Juice Is a Candidate Biomarker for the Detection of Pancreatic Cancer.
    Levink IJM; Srebniak MI; De Valk WG; van Veghel-Plandsoen MM; Wagner A; Cahen DL; Fuhler GM; Bruno MJ
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
    Yu J; Sadakari Y; Shindo K; Suenaga M; Brant A; Almario JAN; Borges M; Barkley T; Fesharakizadeh S; Ford M; Hruban RH; Shin EJ; Lennon AM; Canto MI; Goggins M
    Gut; 2017 Sep; 66(9):1677-1687. PubMed ID: 27432539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer.
    Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Fukasawa Y; Kawakami S; Hayakawa H; Maekawa S; Mochizuki K; Kawaida H; Kono H; Itakura J; Sato T; Ichikawa D; Enomoto N
    Pancreas; 2019 Sep; 48(8):1032-1040. PubMed ID: 31404021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
    Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
    Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype.
    Hata T; Mizuma M; Motoi F; Omori Y; Ishida M; Nakagawa K; Hayashi H; Morikawa T; Kamei T; Furukawa T; Unno M
    Sci Rep; 2020 Oct; 10(1):17761. PubMed ID: 33082481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous and sequential combination of genetic and epigenetic biomarkers for the presence of high-grade dysplasia in patients with pancreatic cyst: Discovery in cyst fluid and test in pancreatic juice.
    Hata T; Mizuma M; Kusakabe T; Amano H; Furukawa T; Iwao T; Unno M
    Pancreatology; 2023 Mar; 23(2):218-226. PubMed ID: 36707261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Sequencing Revealed TP53 Mutations to Be Malignant Marker for Intraductal Papillary Mucinous Neoplasms That Could Be Detected Using Pancreatic Juice.
    Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Maekawa S; Mochizuki K; Kawaida H; Itakura J; Katoh R; Fujii H; Sato T; Enomoto N
    Pancreas; 2017; 46(10):1281-1287. PubMed ID: 28930868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational Mosaics of Cell-Free DNA from Pancreatic Cyst Fluids.
    Paziewska A; Polkowski M; Goryca K; Karczmarski J; Wiechowska-Kozlowska A; Dabrowska M; Mikula M; Ostrowski J
    Dig Dis Sci; 2020 Aug; 65(8):2294-2301. PubMed ID: 31925676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
    Singhi AD; McGrath K; Brand RE; Khalid A; Zeh HJ; Chennat JS; Fasanella KE; Papachristou GI; Slivka A; Bartlett DL; Dasyam AK; Hogg M; Lee KK; Marsh JW; Monaco SE; Ohori NP; Pingpank JF; Tsung A; Zureikat AH; Wald AI; Nikiforova MN
    Gut; 2018 Dec; 67(12):2131-2141. PubMed ID: 28970292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
    Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
    BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and meta-analysis: Diagnostic performance of DNA alterations in pancreatic juice for the detection of pancreatic cancer.
    Visser IJ; Levink IJM; Peppelenbosch MP; Fuhler GM; Bruno MJ; Cahen DL
    Pancreatology; 2022 Nov; 22(7):973-986. PubMed ID: 35864067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.
    Eshleman JR; Norris AL; Sadakari Y; Debeljak M; Borges M; Harrington C; Lin E; Brant A; Barkley T; Almario JA; Topazian M; Farrell J; Syngal S; Lee JH; Yu J; Hruban RH; Kanda M; Canto MI; Goggins M
    Clin Gastroenterol Hepatol; 2015 May; 13(5):963-9.e4. PubMed ID: 25481712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
    Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
    Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
    Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
    Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Utility of Next-Generation Sequencing in Circulating Free DNA and a Comparison With Matched Tissue in Gallbladder Carcinoma.
    Mishra S; Srivastava P; Pandey A; Shukla S; Agarwal A; Husain N
    Lab Invest; 2024 Feb; 104(2):100301. PubMed ID: 38092180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.